Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ANEB Anebulo Pharmaceuticals	$1.55 +5.4%	$1.10	$0.80 ▼ $3.08	$60.40M	-1.15	18,715 shs	7,800 shs
CADL Candel Therapeutics	$4.92 -0.4%	$5.20	$3.79 ▼ $14.60	$247.51M	-0.87	1.47 million shs	874,819 shs
CRDF Cardiff Oncology	$3.02 -18.4%	$3.07	$2.01 ▼ $5.64	$246.15M	1.61	1.19 million shs	3.72 million shs
PVLA Palvella Therapeutics	$20.51 -3.4%	$23.78	$6.20 ▼ $29.27	$234.82M	-0.1	77,898 shs	42,590 shs

13 Stocks Institutional Investors Won't Stop Buying

Which stocks are hedge funds and endowments buying in today's market? Enter your email address and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying now.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ANEB Anebulo Pharmaceuticals	+5.44%	+33.62%	+46.23%	-21.72%	-24.35%
CADL Candel Therapeutics	-0.40%	-9.89%	-13.68%	-40.36%	-26.79%
CRDF Cardiff Oncology	-18.38%	-21.96%	+3.78%	-19.68%	+20.80%
PVLA Palvella Therapeutics	-3.44%	-19.00%	-9.09%	-25.23%	+2,050,999,900.00%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ANEB Anebulo Pharmaceuticals	2.7752 of 5 stars	3.5	5.0	0.0	1.7	0.0
CADL Candel Therapeutics	2.6778 of 5 stars	3.5	3.0	3.2	0.8	0.6
CRDF Cardiff Oncology	1.1664 of 5 stars	3.5	0.0	1.1	0.0	0.6
PVLA Palvella Therapeutics	4.206 of 5 stars	4.6	0.0	3.9	4.2	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ANEB Anebulo Pharmaceuticals	3.00	Buy	$5.50	254.84% Upside
CADL Candel Therapeutics	3.00	Buy	$21.00	326.83% Upside
CRDF Cardiff Oncology	3.00	Buy	$12.00	297.35% Upside
PVLA Palvella Therapeutics	3.13	Buy	$46.29	125.67% Upside

Current Analyst Ratings Breakdown

Latest ANEB, PVLA, CADL, and CRDF Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/18/2025	CRDF Cardiff Oncology	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform
5/16/2025	PVLA Palvella Therapeutics	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$53.00 ➝ $52.00
5/15/2025	ANEB Anebulo Pharmaceuticals	Maxim Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$6.00 ➝ $3.00
5/9/2025	CRDF Cardiff Oncology	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$17.00 ➝ $18.00
4/30/2025	PVLA Palvella Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$38.00 ➝ $38.00
4/11/2025	CADL Candel Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$19.00 ➝ $19.00
4/9/2025	PVLA Palvella Therapeutics	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$50.00
4/1/2025	PVLA Palvella Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$38.00 ➝ $38.00
3/26/2025	PVLA Palvella Therapeutics	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$45.00
3/25/2025	PVLA Palvella Therapeutics	Jones Trading Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$45.00
3/24/2025	PVLA Palvella Therapeutics	Jones Trading Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy

(Data available from 6/19/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ANEB Anebulo Pharmaceuticals	N/A	N/A	N/A	N/A	$0.15 per share	N/A
CADL Candel Therapeutics	$120K	2,054.10	N/A	N/A	$1.41 per share	3.49
CRDF Cardiff Oncology	$680K	295.47	N/A	N/A	$1.86 per share	1.62
PVLA Palvella Therapeutics	$42.81M	5.30	N/A	N/A	$5.58 per share	3.68

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ANEB Anebulo Pharmaceuticals	-$8.20M	-$0.26	N/A	∞	N/A	N/A	-90.11%	-84.53%	N/A
CADL Candel Therapeutics	-$55.18M	-$1.34	N/A	N/A	N/A	N/A	-136.74%	-63.13%	8/12/2025 (Estimated)
CRDF Cardiff Oncology	-$45.43M	-$0.92	N/A	N/A	N/A	-8,308.50%	-76.45%	-62.85%	8/14/2025 (Estimated)
PVLA Palvella Therapeutics	-$17.43M	-$12.10	N/A	N/A	N/A	N/A	-60.29%	-43.30%	8/13/2025 (Estimated)

Latest ANEB, PVLA, CADL, and CRDF Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/15/2025	Q1 2025	PVLA Palvella Therapeutics	-$3.40	-$0.74	+$2.66	-$0.74	N/A	N/A
5/13/2025	Q3 2025	ANEB Anebulo Pharmaceuticals	-$0.05	-$0.04	+$0.01	-$0.04	N/A	N/A
5/13/2025	Q1 2025	CADL Candel Therapeutics	-$0.24	$0.13	+$0.37	$0.13	N/A	N/A
5/8/2025	Q1 2025	CRDF Cardiff Oncology	-$0.19	-$0.20	-$0.01	-$0.20	$0.09 million	$0.11 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ANEB Anebulo Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
CADL Candel Therapeutics	N/A	N/A	N/A	N/A	N/A
CRDF Cardiff Oncology	N/A	N/A	N/A	N/A	N/A
PVLA Palvella Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ANEB Anebulo Pharmaceuticals	N/A	25.29	25.29
CADL Candel Therapeutics	0.01	4.64	4.64
CRDF Cardiff Oncology	N/A	6.22	6.22
PVLA Palvella Therapeutics	N/A	8.84	8.84

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ANEB Anebulo Pharmaceuticals	28.40%
CADL Candel Therapeutics	13.93%
CRDF Cardiff Oncology	16.29%
PVLA Palvella Therapeutics	40.11%

Insider Ownership

Company	Insider Ownership
ANEB Anebulo Pharmaceuticals	80.60%
CADL Candel Therapeutics	16.60%
CRDF Cardiff Oncology	7.70%
PVLA Palvella Therapeutics	20.50%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ANEB Anebulo Pharmaceuticals	4	41.08 million	7.97 million	Not Optionable
CADL Candel Therapeutics	60	50.10 million	41.79 million	Optionable
CRDF Cardiff Oncology	20	66.53 million	61.40 million	Optionable
PVLA Palvella Therapeutics	N/A	11.06 million	8.79 million	N/A

ANEB, PVLA, CADL, and CRDF Headlines

Recent News About These Companies

Palvella Therapeutics Granted Sixth U.S. Patent Covering 0.1–20% Anhydrous Compositions of Rapamycin and Other mTOR Inhibitors

June 18 at 7:30 AM | globenewswire.com

Palvella Therapeutics Secures FDA Grant Funding for Phase 3 Trial of QTORIN Rapamycin

June 13, 2025 | msn.com

Cantor Fitzgerald Weighs in on PVLA FY2026 Earnings

June 13, 2025 | americanbankingnews.com

Palvella Therapeutics (NASDAQ:PVLA) Receives $46.29 Average Target Price from Brokerages

June 13, 2025 | americanbankingnews.com

Cantor Fitzgerald Comments on PVLA FY2026 Earnings

June 11, 2025 | marketbeat.com

Palvella Therapeutics Secures FDA Orphan Products Grant to Support Phase 3 SELVA Trial of QTORIN™ for Microcystic Lymphatic Malformations

June 9, 2025 | quiverquant.com

Palvella Therapeutics Receives Initial Proceeds from FDA Orphan Products Grant to Support Phase 3 SELVA Trial of QTORIN™ Rapamycin for Microcystic Lymphatic Malformations

June 9, 2025 | globenewswire.com

Citadel Advisors LLC Makes New Investment in Palvella Therapeutics (NASDAQ:PVLA)

June 9, 2025 | marketbeat.com

Palvella Therapeutics (NASDAQ:PVLA) Given Consensus Recommendation of "Buy" by Analysts

June 8, 2025 | marketbeat.com

Toronto Dominion Bank Buys Shares of 13,211 Palvella Therapeutics (NASDAQ:PVLA)

June 2, 2025 | marketbeat.com

Palvella Therapeutics Advances in Rare Skin Disease Therapies

May 31, 2025 | tipranks.com

Palvella Therapeutics Strengthens Executive Leadership Team with Appointment of Rare Disease Commercial Veteran Ashley Kline as Chief Commercial Officer

May 27, 2025 | globenewswire.com

Toronto Dominion Bank Takes Position in Palvella Therapeutics (NASDAQ:PVLA)

May 27, 2025 | marketbeat.com

Cantor Fitzgerald Predicts PVLA FY2025 Earnings

May 23, 2025 | marketbeat.com

Frazier Life Sciences Management L.P. Invests $7.85 Million in Palvella Therapeutics (NASDAQ:PVLA)

May 23, 2025 | marketbeat.com

Cresset Asset Management LLC Purchases New Holdings in Palvella Therapeutics (NASDAQ:PVLA)

May 20, 2025 | marketbeat.com

Suvretta Capital Management LLC Takes $8.57 Million Position in Palvella Therapeutics (NASDAQ:PVLA)

May 19, 2025 | marketbeat.com

Why Palvella Therapeutics, Inc.’s (PVLA) Stock Is Up 5.55%

May 16, 2025 | aaii.com

Promising Outlook for Palvella Therapeutics: Buy Rating Affirmed by Andrew Fein Due to Phase 3 SELVA Trial Success and Strategic Market Position

May 16, 2025 | tipranks.com

Palvella Therapeutics Inc (PVLA) Q1 2025 Earnings Call Highlights: Strong Clinical Progress ...

May 16, 2025 | finance.yahoo.com

Q1 2025 Palvella Therapeutics Inc Earnings Call Transcript

May 16, 2025 | gurufocus.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ANEB, PVLA, CADL, and CRDF Company Descriptions

Anebulo Pharmaceuticals NASDAQ:ANEB

$1.55 +0.08 (+5.44%)

Closing price 06/18/2025 04:00 PM Eastern

Extended Trading

$1.48 -0.08 (-4.84%)

As of 06/18/2025 05:00 PM Eastern

Anebulo Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing solutions for people suffering from acute cannabinoid intoxication (ACI) and substance addiction. The company's lead product candidate is ANEB-001, a small molecule cannabinoid receptor antagonist, which is in a Phase II clinical trial to address the unmet medical need for a specific antidote for ACI. Anebulo Pharmaceuticals, Inc. was incorporated in 2020 and is based in Lakeway, Texas.

Candel Therapeutics NASDAQ:CADL

$4.92 -0.02 (-0.40%)

Closing price 06/18/2025 04:00 PM Eastern

Extended Trading

$5.04 +0.12 (+2.34%)

As of 06/18/2025 07:57 PM Eastern

Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. It develops CAN-2409, which is in Phase II clinical trials for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the treatment of lung cancer, as well as has completed Phase Ib/II clinical trials for the treatment of high-grade glioma. The company also develops CAN-3110, which is in Phase I clinical trials for the treatment of recurrent high-grade glioma. It also develops the?enLIGHTEN Discovery Platform, a systematic, iterative HSV-based discovery platform leveraging human biology and advanced analytics to create new viral immunotherapies for solid tumors. The company was formerly known as Advantagene, Inc. and changed its name to Candel Therapeutics, Inc. in November 2020. Candel Therapeutics, Inc. was incorporated in 2003 and is headquartered in Needham, Massachusetts.

Cardiff Oncology NASDAQ:CRDF

$3.02 -0.68 (-18.38%)

Closing price 06/18/2025 04:00 PM Eastern

Extended Trading

$3.05 +0.03 (+0.99%)

As of 06/18/2025 07:55 PM Eastern

Cardiff Oncology, Inc., a clinical-stage biotechnology company, develops novel therapies to treat various cancers in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor to treatment a range of solid tumor cancers and KRAS/NRAS-mutated metastatic colorectal and metastatic pancreatic cancer, as well as investigator-initiated trials in triple negative breast cancer and small cell lung cancer; and TROV-054 is a Phase 1b/2 for FOLFIRI and bevacizumab. The company primarily serves pharmaceutical manufacturers. The company was formerly known as Trovagene, Inc. and changed its name to Cardiff Oncology, Inc. in May 2012. Cardiff Oncology, Inc. was incorporated in 1999 and is headquartered in San Diego, California.

Palvella Therapeutics NASDAQ:PVLA

$20.51 -0.73 (-3.44%)

As of 06/18/2025 04:00 PM Eastern

Palvella Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases. Palvella Therapeutics Inc., formerly known as Pieris Pharmaceuticals Inc., is based in WAYNE, Pa.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time